查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790252

美国抗生素市场规模、份额及趋势分析报告：按作用机制、类型、药物类别和细分市场进行预测，2025-2030 年

U.S. Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism, By Type, By Drug Class, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国抗生素市场概况

美国抗生素市场规模预计在 2024 年达到 137.7 亿美元，预计在 2025 年至 2030 年期间的复合年增长率为 3.0%，到 2030 年将达到 164.6 亿美元。感染疾病的日益普及是市场成长的主要动力。

老年人和慢性疾病患者中感染疾病的普遍性是美国抗生素市场的主要驱动力。到2024年，超过6,000万美国将年满65岁或以上，这使得他们更容易感染肺炎、尿道结石和败血症等感染疾病。此外，糖尿病、癌症和慢性阻塞性肺病（COPD）等慢性疾病的盛行率不断上升，削弱了免疫系统，增加了对抗生素的需求。根据美国疾病管制与预防中心（CDC）的数据，近60%的美国成年人至少患有一种慢性疾病，这进一步扩大了需要抗生素治疗的患者群体。

外科手术和先进医疗干预措施的兴起是美国市场抗生素需求成长的主要原因。器官移植、癌症治疗和整形外科手术等手术通常具有较高的术后感染疾病风险，因此预防性和治疗性抗生素至关重要。医院和门诊机构依靠有效的抗生素方案来减少併发症并改善患者康復。随着这些手术的可及性不断扩大，抗生素在确保患者获得良好治疗结果方面发挥更重要的作用，巩固了其作为现代医学重要组成部分的地位。

美国抗生素市场蓬勃发展，得益于尖端研发、巨额医疗支出以及对创新的高度重视。美国在开发用于对抗抗药性的下一代抗生素方面处于全球领先地位，并得到了2012年《立即产生抗生素激励法案》（GAIN）等倡议的支持。一个显着的例子是默克与美国国家过敏和感染疾病研究所（NIAID）于2023年达成的合作，旨在开发针对多重抗药性细菌的新型抗生素。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国抗生素市场变数、趋势与范围

  • 市场介绍/电网展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国抗生素市场分析工具
    • 波特分析
    • PESTEL分析

第四章美国抗生素市场：按作用机制的估计与趋势分析

  • 细分仪表板
  • 美国抗生素市场：作用机制分析（2023 年和 2030 年）
  • 细胞壁合成抑制剂
    • 2018-2030年收益估算与预测
  • 蛋白质合成抑制剂
    • 2018-2030年收益估算与预测
  • DNA合成抑制剂
    • 2018-2030年收益估算与预测
  • RNA合成抑制剂
    • 2018-2030年收益估算与预测
  • 肌酸抑制剂
    • 2018-2030年收益估算与预测
  • 其他的
    • 2018-2030年收益估算与预测

第五章：美国抗生素市场类型、估价与趋势分析

  • 细分仪表板
  • 美国抗生素市场：2023 年和 2030 年类型分析
  • 品牌抗生素
    • 2018-2030年收益估算与预测
  • 非专利药
    • 2018-2030年收益估算与预测

第六章：美国抗生素市场（依药物类别划分）、估价与趋势分析

  • 细分仪表板
  • 美国抗生素市场：2023 年和 2030 年药物类别分析
  • 头孢菌素类
    • 2018-2030年收益估算与预测
  • 青霉素
    • 2018-2030年收益估算与预测
  • Fluoroquinolones
    • 2018-2030年收益估算与预测
  • 大环内酯类
    • 2018-2030年收益估算与预测
  • 卡巴培南类
    • 2018-2030年收益估算与预测
  • Aminoglycosides
    • 2018-2030年收益估算与预测
  • 磺胺类药物
    • 2018-2030年收益估算与预测
  • 7-ACA
    • 2018-2030年收益估算与预测
  • 其他的
    • 2018-2030年收益估算与预测

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 公司热图分析
  • 公司简介
    • AbbeVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-683-7

U.S. Antibiotics Market Summary

The U.S. antibiotics market size was estimated at USD 13.77 billion in 2024 and is projected to reach USD 16.46 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing prevalence of infectious diseases is a major factor contributing to market growth.

The increasing prevalence of infections in the elderly and chronically ill significantly drives the U.S. antibiotics market. In 2024, over 60 million Americans were aged 65 or older, a demographic highly susceptible to infections like pneumonia, UTIs, and sepsis. In addition to that, the rising incidence of chronic conditions such as diabetes, cancer, and COPD compromises immune systems, leading to a greater need for antibiotics. According to CDC, nearly 60% of U.S. adults have at least one chronic disease, further expanding the patient base requiring antibiotic treatment.

The increasing number of surgical procedures and advanced medical interventions significantly contribute to the demand for antibiotics in the U.S. market. Procedures such as organ transplants, cancer treatments, and orthopedic surgeries often carry a high risk of post-operative infections, making preventive and therapeutic antibiotics essential. Hospitals and outpatient facilities depend on effective antibiotic regimens to reduce complications and improve patient recovery. As access to these procedures expands, antibiotics play an even more critical role in ensuring positive patient outcomes, solidifying their position as a vital part of modern medical care.

The U.S. antibiotics market is growing due to cutting-edge R&D, substantial healthcare spending, and a strong emphasis on innovation. The country leads globally in developing next-generation antibiotics to counter AMR, supported by policies such as the Generating Antibiotic Incentives Now (GAIN) Act of 2012, which provides incentives such as extended exclusivity periods. A notable instance is the collaboration between Merck and the National Institute of Allergy and Infectious Diseases (NIAID) in 2023 to develop novel antibiotics targeting multidrug-resistant bacteria.

U.S. Antibiotics Market Report Segmentation

This report forecasts revenue growth at country level as well as provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. antibiotics market report on the basis of action mechanism, type, and drug class:

  • Action Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Branded Antibiotics
  • Generic Anitbiotics
  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • 7-ACA
  • Other

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
  • 1.4. Information Procurement
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. U.S. Antibiotics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Political landscape
      • 3.4.1.2. Economic and Social landscape
      • 3.4.1.3. Technological landscape
      • 3.4.1.4. Environmental landscape
      • 3.4.1.5. Legal landscape
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Bargaining power of the suppliers
      • 3.4.2.2. Bargaining power of the buyers
      • 3.4.2.3. Threats of substitution
      • 3.4.2.4. Threats from new entrants
      • 3.4.2.5. Competitive rivalry

Chapter 4. U.S. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Antibiotics Market: Action Mechanism Analysis, 2023 & 2030 (USD Million)
  • 4.3. Cell Wall Synthesis Inhibitors
    • 4.3.1. Cell Wall Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Protein Synthesis Inhibitors
    • 4.4.1. Protein Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. DNA Synthesis Inhibitors
    • 4.5.1. DNA Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. RNA Synthesis Inhibitors
    • 4.6.1. RNA Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Mycolic Acid Inhibitors
    • 4.7.1. Mycolic Acid Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Antibiotics Market: Type Analysis, 2023 & 2030 (USD Million)
  • 5.3. Branded Antibiotics
    • 5.3.1. Branded Antibiotics Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Generic Antibiotics
    • 5.4.1. Generic Antibiotics Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Antibiotics Market: Drug Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Antibiotics Market: Drug Analysis, 2023 & 2030 (USD Million)
  • 6.3. Cephalosporins
    • 6.3.1. Cephalosporins Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Penicillin
    • 6.4.1. Penicillin Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Fluoroquinolones
    • 6.5.1. Fluoroquinolones Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Macrolides
    • 6.6.1. Macrolides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Carbapenems
    • 6.7.1. Carbapenems Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Aminoglycosides
    • 6.8.1. Aminoglycosides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Sulfonamides
    • 6.9.1. Sulfonamides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. 7-ACA
    • 6.10.1. 7-ACA Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Mycolic Acid Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. AbbeVie, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Merck & Co., Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Antibiotics market 2018 - 2030 (USD Million)
  • Table 3 U.S. antibiotics market: key market driver analysis
  • Table 4 U.S. antibiotics market: key market restraint analysis
  • Table 5 U.S. antibiotics market estimates and forecast, by action mechanism (USD Million)
  • Table 6 U.S. antibiotics market estimates and forecast, by type (USD Million)
  • Table 7 U.S. antibiotics market estimates and forecast, by drug class (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antibiotics products: market outlook
  • Fig. 10 Diabetic retinopathy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antibiotics driver impact
  • Fig. 16 U.S. antibiotics restraint impact
  • Fig. 17 U.S. antibiotics strategic initiatives analysis
  • Fig. 18 U.S. antibiotics products: Action Mechanism movement analysis
  • Fig. 19 U.S. antibiotics products: Action Mechanism outlook and key takeaways
  • Fig. 20 Cell Wall Synthesis Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 21 Protein Synthesis Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 22 DNA Synthesis Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 23 RNA Synthesis Inhibitors estimate and forecast, 2018 - 2030
  • Fig. 24 Mycolic Acid Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 25 Others estimates and forecast, 2018 - 2030
  • Fig. 26 U.S. antibiotics products: Type movement analysis
  • Fig. 27 U.S. antibiotics products: Type outlook and key takeaways
  • Fig. 28 Branded Antibiotics market estimates and forecasts, 2018 - 2030
  • Fig. 29 General Antibiotics market estimates and forecasts,2018 - 2030
  • Fig. 30 U.S. antibiotics products: Drug class movement analysis
  • Fig. 31 U.S. antibiotics products: Drug class outlook and key takeaways
  • Fig. 32 Cephalosporins market estimates and forecasts, 2018 - 2030
  • Fig. 33 Penicillins market estimates and forecasts,2018 - 2030
  • Fig. 34 Flaoroquinolones market estimates and forecasts,2018 - 2030
  • Fig. 35 Macrolides market estimates and forecasts,2018 - 2030
  • Fig. 36 Carbopenems market estimates and forecasts,2018 - 2030
  • Fig. 37 Aminoglycosides market estimates and forecasts,2018 - 2030
  • Fig. 38 Sulfonamides market estimates and forecasts,2018 - 2030
  • Fig. 39 7-ACA market estimates and forecasts,2018 - 2030
  • Fig. 40 Other market estimates and forecasts,2018 - 2030